Search

#DiabetesManagement

Antonio Sabato Jr 2w

Retatrutide is an investigational once-weekly injectable medication that targets three metabolic receptors—GLP-1, GIP, and glucagon—to suppress appetite, optimize insulin secretion, and increase energy expenditure. Clinical trials show it drives substantial weight loss. That’s #Retatrutide #WeightLoss #DiabetesManagement #Thetweetdoesnotmentionanyspecificcountries.Therefore #therearenocountrycodestoreturn.

WebMD Mar 23

#DiabetesManagement #HealthyEating #InsulinResistance

Could Insulin-Resistance Diet Lower Your Diabetes Risk?

Fortune Mar 19

#HealthCare #AffordableCareAct #DiabetesManagement

'Sometimes I don't even take my medicine': Americans are choosing between insulin and buying gas following Trump's Obamacare cuts | Fortune

AP NEWS Mar 19

#HealthCare #AffordableCareAct #DiabetesManagement

What ACA enrollees are cutting back on to afford health care, according to a new poll

Harvard T.H. Chan School of Public Health Feb 26

#DiabetesManagement #HeartHealth #HealthyLifestyle

GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients | Harvard T.H. Chan School of Public Health

Business Insider Feb 26

#GLP1 #WeightLoss #DiabetesManagement

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch.

Aol Jan 23

#DiabetesManagement #HealthAwareness #ChronicIllness

5 Diabetes Breakthroughs: New Tools to Control Blood Sugar

Aol Jan 23

#DiabetesManagement #HealthAwareness #ChronicIllness

5 Diabetes Breakthroughs: New Tools to Control Blood Sugar

U.S. News & World Report Jan 22

#GLP1 #ObesityTreatment #DiabetesManagement

GLP-1 Medications: A Comprehensive Overview